How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Fibrosis Drug Market
- By Fibrosis Type: Pulmonary Fibrosis, Liver Fibrosis, Cardiac Fibrosis, Renal Fibrosis, Systemic Sclerosis
- By Drug Class: Antifibrotic Agents, Immunosuppressants, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Corticosteroids
- By Route of Administration: Oral, Intravenous, Subcutaneous, Inhalation
- By Mechanism of Action: TGF-β Inhibitors, Angiotensin Receptor Blockers, Matrix Metalloproteinase Modulators, Integrin Antagonists
- By Patient Population: Idiopathic Fibrosis Patients, Post-Transplant Fibrosis Patients, Chronic Disease-Associated Fibrosis Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pulmonary Fibrosis leads By Fibrosis Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Fibrosis Drug Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Fibrosis Type 5
Drug Class 5
Route of Administration 4
Mechanism of Action 4
Patient Population 3
Companies profiled
Roche
Boehringer Ingelheim
Gilead Sciences
InterMune (a subsidiary of Roche)
Galapagos NV
Mitsubishi Tanabe Pharma Corporation
Bristol-Myers Squibb
FibroGen Inc.
Johnson & Johnson
AbbVie
Novartis
Pfizer
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boehringer Ingelheim
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →InterMune (a subsidiary of Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Galapagos NV
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mitsubishi Tanabe Pharma Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →FibroGen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AbbVie
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Novartis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Pfizer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Eli Lilly and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →AstraZeneca
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,862M by 2033 · 8.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pulmonary Fibrosis45.7
- Liver Fibrosis9.7
- Cardiac Fibrosis13.5
- Renal Fibrosis17.2
- Systemic Sclerosis13.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,714M → $3,440M · 9.1%
Europe$1,194M → $2,282M · 8.4%
Asia Pacific$1,091M → $2,023M · 8.0%
Latin America$675.1M → $1,219M · 7.7%
Middle East and Africa$519.3M → $1,062M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.312026
8.312027
8.332028
8.342029
8.342030
8.362031
8.372032
8.382033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche23.1
- Boehringer Ingelheim10.3
- Gilead Sciences8.4
- InterMune (a subsidiary of Roche)7.4
- Galapagos NV10.8
- Mitsubishi Tanabe Pharma Corporation12.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Fibrosis Type14.4%
Drug Class20.5%
Route of Administration15.1%
Mechanism of Action24.4%
Patient Population25.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe22.8
- Asia Pacific20.2
- Latin America12.2
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 90 | 90 | 79 | 90 | 99 | 97 | 91 |
| Boehringer Ingelheim | 77 | 70 | 89 | 71 | 84 | 72 | 77 |
| Gilead Sciences | 72 | 86 | 87 | 69 | 62 | 80 | 76 |
| InterMune (a subsidiary of Roche) | 72 | 70 | 76 | 64 | 61 | 79 | 70 |
| Galapagos NV | 73 | 64 | 56 | 69 | 64 | 68 | 66 |
| Mitsubishi Tanabe Pharma Corporation | 64 | 60 | 46 | 58 | 70 | 71 | 62 |
| Bristol-Myers Squibb | 48 | 40 | 41 | 65 | 55 | 61 | 52 |
| FibroGen Inc. | 42 | 54 | 53 | 40 | 50 | 60 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Boehringer Ingelheim
- Gilead Sciences
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Boehringer Ingelheim | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Gilead Sciences | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| InterMune (a subsidiary of Roche) | ◐ | − | ✓ | ◐ | − | ✓ |
| Galapagos NV | − | ◐ | ◐ | ✓ | ◐ | − |
| Mitsubishi Tanabe Pharma Corporation | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Bristol-Myers Squibb | − | − | ◐ | − | − | − |
| FibroGen Inc. | − | ◐ | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche91
2Boehringer Ingelheim77
3Gilead Sciences76
4InterMune (a subsidiary of Roche)70
5Galapagos NV66
6Mitsubishi Tanabe Pharma Corporation62
7Bristol-Myers Squibb52
8FibroGen Inc.50
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche
Challenger3
Strong scale, closing on the leaders.
Boehringer IngelheimGilead SciencesInterMune (a subsidiary of Roche)
Contender2
Focused players with pockets of strength.
Galapagos NVMitsubishi Tanabe Pharma Corporation
Niche2
Specialists in a single segment or region.
Bristol-Myers SquibbFibroGen Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Fibrosis Type in North America, then scale across Fibrosis Drug Market — a $126M beachhead inside a $2.05B market.
Beachhead (SOM)$126Mobtainable near-term
Serviceable (SAM)$787Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Pulmonary Fibrosis
Best fit — highest urgency & budget in Fibrosis Type.
Economic buyer77 fit
Liver Fibrosis
Strong fit — clear ROI and a fast path to value.
End user67 fit
Cardiac Fibrosis
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Fibrosis Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Fibrosis Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Fibrosis Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation11%
Closed-won7%
$16.3KCAC
$74KLTV
4.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Fibrosis Drug Market is a durable-growth opportunity — $5.28B by 2033, compounding at 7.5%.
TAM · 2025$2.97Btoday
TAM · 2033$5.28Bforecast
CAGR7.5%2027–2033
Cumulative$36.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.28BTotal addressable market
SAM$1.81BServiceable available market
SOM$341MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.5% CAGR
Demand compounds through 2033, outpacing GDP across Fibrosis Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Fibrosis Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.28BLarge & growingTAM by 2033 at 7.5% CAGR
$1.81BServiceable nowreachable with today’s model
$341MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.12BBear4.9% CAGR
$5.28BBase7.5% CAGR
$6.76BBull9.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Fibrosis Drug Market — a $6.29B market by 2033. Plan: grow share from 6.8% to 13.5%.
Market size · 2033$6.29Btotal addressable
Market CAGR7.8%2027–2033
Target share13.5%from 6.8% today
Revenue ambition$849Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 13.5% | Behind |
| Revenue | $411M | $849M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.8% | 42.2% | At risk |
| Customer retention | 86.0% | 96.4% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Fibrosis Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Fibrosis Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $111M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Fibrosis Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Fibrosis Drug Market conversation — a $7.78B market you can size, segment and defend in minutes.
Market size · 2033$7.78Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,065+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Fibrosis Type
Goal Grow share in Fibrosis Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheBoehringer IngelheimGilead SciencesInterMune (a subsidiary of Roche)Galapagos NVMitsubishi Tanabe Pharma CorporationBristol-Myers SquibbFibroGen Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Fibrosis Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Fibrosis Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Fibrous Filters Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportFibrous Glass Reinforced Plastics Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFibrous Insulation Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportFicin Proteinase Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportFidelity Sound Receiver Market
Market size, share, segmentation and regional forecast.
$751M market · 2025 base year
View reportFIDO Device Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportFiducial Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportField Artillery Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportField Assembly Optical Connector Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportField Cultivators Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportField Effect Transistor Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportField Effect Transistors(Fets) Market
Market size, share, segmentation and regional forecast.
$612M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.